Results underscore clinical utility of novel circulating tumor DNA assay to detect disease recurrence
BRIDGEWATER, N.J., Oct. 12, 2016 -- Clinical Genomics, a private company developing innovative diagnostic tools for colorectal cancer, today announced that data supporting its two-gene circulating tumor DNA (ctDNA) blood test for post-surgical monitoring of colorectal cancer (CRC) recurrence have been published online by Cancer Medicine, and will appear in the October issue.
Results demonstrate that the Company’s test detects twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard of care component for CRC recurrence monitoring in patients who have undergone surgery. The test measures the presence of BCAT1 and IKZF1 gene methylation, a chemical modification associated with tumor growth and invasion. Preliminary data from this study were presented in January at the American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium (ASCO GI).
“Given that at least 30 percent of patients in remission from CRC following initial treatment will develop recurrence, improved surveillance methods that accurately detect recurrence are essential for improving outcomes for patients,” said contributing study author Dr. Graeme P Young, Matthew Flinders Distinguished Professor, Flinders University Centre for Innovation in Cancer, Adelaide Australia. “Data from this study reinforce previous findings that ctDNA can be reliably detected in CRC patients. Furthermore, the results suggest that when used in ongoing surveillance of cases in remission, a positiveBCAT1/IKZF1 test has the potential to establish a new approach for earlier detection of recurrent CRC by detecting more unsuspected recurrences and triggering earlier imaging studies. Additional prospective studies of the methylated BCAT1/IKZF1 test compared with CEA are ongoing.”
CRC is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but only approximately four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 40 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.
This study compared the sensitivity and specificity of the two-gene blood test for methylated BCAT1 andIKZF1 with those of CEA in patients undergoing surveillance for recurrent CRC following induction of remission. Recurrence was assessed by clinical findings, blood testing and periodic computed tomographic surveillance scans. A total of 357 volunteers were recruited. Recurrence status could be established for 220 subjects, of which 122 had blood samples available for analysis. Of the 122 participants evaluated, 28 had recurrence and 94 had no clinically-detectable disease. Among those with recurrent disease, 67.9 percent (19/28) were positive for methylated BCAT1/IKZF1 (i.e. marker was detectable) while only 32.1 percent (9/28) were positive for CEA (>5 ng/mL), representing a significant two-fold detection improvement with the two-gene test. Among the 94 patients without clinically detectable recurrence there was no significant difference in the percentage positive for methylatedBCAT1/IKZF1 compared to CEA.
In this study population, sensitivity estimates of the methylated BCAT1/IKZF1 test were 75 percent and 66.7 percent for local and distant recurrence, respectively, compared with 50 percent and 29.2 percent for CEA. Nine patients were positive for both tests, while the two-gene test detected an additional 10 cases that CEA failed to detect in the blood sample collected closest to the time of radiologic assessment for recurrence. “An inability to detect early molecular changes consistent with underlying tumorigenesis can result in recurrent colorectal cancer going undetected or being discovered in the later stages of disease when clinical intervention is less likely to be effective,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “These data demonstrate that a blood-based ctDNA test for methylated BCAT1/IKZF1routinely detects recurrence that CEA testing misses. We believe our two-gene test has the potential to fill an urgent and unmet clinical need, and are committed to advancing its clinical development as a new tool for improving patient outcomes.”
About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred colorectal cancer screening InSure® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of CRC screening and diagnosis, Clinical Genomics developed a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer based on methylated DNA from two genes, BCAT1 and IKZF1. The Company plans to offer this two-gene test for recurrence monitoring later in 2016.
Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory. For more information, please visit www.clinicalgenomics.com.
